Stocks · News reference
Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay Attention
Corporate executives say optimistic things about their companies every day. They appear on earnings calls, investor presentations and financial television programs to explain why the latest disappointing quarter is
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 7:29 PM
- Checked
- Jul 24, 2026, 7:29 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
UBS Maintains Buy on Hamilton Lane, Raises Price Target to $131
UBS analyst Michael Brown maintains Hamilton Lane (NASDAQ:HLNE) with a Buy and raises the price target from $114 to $131.
Read original at benzingaOppenheimer Maintains Outperform on Hamilton Lane, Raises Price Target to $182
Oppenheimer analyst Chris Kotowski maintains Hamilton Lane (NASDAQ:HLNE) with a Outperform and raises the price target from $174 to $182.
Read original at benzingaKeefe, Bruyette & Woods Maintains Outperform on Hamilton Lane, Raises Price Target to $116
Keefe, Bruyette & Woods analyst Kyle Voigt maintains Hamilton Lane (NASDAQ:HLNE) with a Outperform and raises the price target from $105 to $116.
Read original at benzingaSMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.
Read original at zacks-investment-researchSummit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.
Read original at benzinga